The gonadotropin-releasing hormone (gnrh) agonist global market report 2024from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Gonadotropin-Releasing Hormone (GnRH) Agonist Market, 2024The gonadotropin-releasing hormone (gnrh) agonist global market report 2024
Market Size –
The gonadotropin-releasing hormone (GnRH) agonist market size has grown steadily in recent years. It will grow from $3.99 billion in 2023 to $4.1 billion in 2024 at a compound annual growth rate (CAGR) of 2.7%. The growth in the historic period can be attributed to rising awareness and diagnosis of hormonal disorders, increasing prevalence of hormone-related diseases, increasing prevalence of prostate cancer, growing awareness about hormone therapy, increase demand for long-term safety and efficacy.
The gonadotropin-releasing hormone (GnRH) agonist market size is expected to see steady growth in the next few years. It will grow to $4.6 billion in 2028 at a compound annual growth rate (CAGR) of 2.9%. The growth in the forecast period can be attributed to rising awareness and early diagnosis, rising healthcare expenditure, increasing use in fertility treatments, rising demand for personalized medicine, and increasing research funding and grants. Major trends in the forecast period include advancements in drug delivery systems, advancements in oncology and reproductive medicine, growing demand for hormone therapy options, increasing research and development, and rise of long-acting formulations.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/gonadotropin-releasing-hormone-gnrh-agonist-global-market-report
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Market Drivers –
The rising prevalence of hormone-related diseases is anticipated to drive the growth of the gonadotropin-releasing hormone (GnRH) agonist market in the coming years. Hormone-related disorders arise from imbalances or dysfunctions in the endocrine system, which regulates hormone production. These disorders include conditions such as diabetes, hyperthyroidism, and prostate cancer. The increasing incidence of hormone-related diseases is attributed to various factors, including environmental influences, obesity and metabolic syndrome, genetics, and an aging population. GnRH agonists are essential for effectively managing hormone levels and offer a tailored approach to treating issues associated with hormonal imbalances and related diseases. For instance, in June 2024, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, reported that there were 236,659 newly diagnosed cases of prostate cancer in the United States in 2021, and 33,363 men died from this disease in 2022. Consequently, the growing prevalence of hormone-related diseases is significantly contributing to the growth of the gonadotropin-releasing hormone (GnRH) agonist market through 2023, into 2024, and expectedly beyond to 2028.
Market Trends –
Major companies operating in the gonadotropin-releasing hormone (GnRH) agonist market are developing advanced androgen deprivation therapy drugs to enhance the effectiveness and precision of treatment for hormone-sensitive cancers. androgen deprivation therapy (ADT) drugs, including gonadotropin-releasing hormone (GnRH) analogs, reduce or eliminate androgen levels to slow or halt hormone-sensitive cancer growth. For instance, in January 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched Relugolix under the brand name Rexigo. It is India’s first and only once-daily oral therapy for testosterone suppression in advanced prostate cancer, eliminating the need for injectable treatments. This convenient oral option features Relugolix, a globally recognized active ingredient that delivers rapid testosterone suppression. Rexigo is 50% more affordable than existing injectable alternatives for advanced prostate cancer in India. Its introduction represents a major advancement in prostate cancer care, offering a safe, effective, and user-friendly treatment choice for both patients and healthcare providers.
The gonadotropin-releasing hormone (GnRH) agonist market covered in this report is segmented –
1) By Type: Leuprorelin, Goserelin, Taltirelin, Histrelin, Other Types
2) By Formulation: Injectable, Implants, Oral, Nasal Sprays
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Prostate Cancer, Breast Cancer, Endometriosis, Uterine Fibroids, Precocious Puberty, Fertility Treatment, Other Applications
5) By End-User: Hospital, Specialty Clinics, Ambulatory Surgical Centers (ASCs), Other End-Users
Get an inside scoop of the gonadotropin-releasing hormone (gnrh) agonist market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=18814&type=smp
Regional Insights –
North America was the largest region in the gonadotropin-releasing hormone (GnRH) agonist market in 2023. The regions covered in the gonadotropin-releasing hormone (GnRH) agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies in the market are Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Sandoz Group AG, Ipsen Pharma, Aurobindo Pharma Limited, Cipla Limited, Dr Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., Ferring Pharmaceuticals, Amneal Pharmaceuticals Inc., Endo International plc, Lupin Limited, Gland Pharma Limited, Glenmark Pharmaceuticals Ltd., Zydus Lifesciences Limited, Bachem Holding AG, Tolmar Pharmaceuticals Inc., Debiopharm Group, Sun Pharmaceutical Industries Ltd.
Table of Contents
1. Executive Summary
2. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Report Structure
3. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Trends And Strategies
4. Gonadotropin-Releasing Hormone (GnRH) Agonist Market – Macro Economic Scenario5. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Size And Growth
…..
27. Gonadotropin-Releasing Hormone (GnRH) Agonist Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
